Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Protein-based Immunotherapies
100,0
%
| 30 | 100,0 % | 59 | 100,0 % | +95,84 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 30 | 100,0 % | 59 | 100,0 % | +95,84 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Mitchell Gold
CEO | Chief Executive Officer | 57 | 24.07.17 |
Director of Finance/CFO | - | 01.06.17 | |
Stanford Peng
PSD | President | 53 | 24.07.17 |
James Rickey
DFI | Director of Finance/CFO | 45 | 24.07.17 |
Christina Yi
CTO | Chief Tech/Sci/R&D Officer | 48 | 21.08.23 |
Wolfgang Dummer
CTO | Chief Tech/Sci/R&D Officer | 58 | 02.10.23 |
Temre Johnson
IRC | Investor Relations Contact | - | - |
Remy Durand
PRN | Corporate Officer/Principal | 38 | 01.01.18 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Robert Conway
BRD | Director/Board Member | 70 | 01.07.17 |
Mitchell Gold
CEO | Chief Executive Officer | 57 | 24.07.17 |
James Topper
BRD | Director/Board Member | 62 | 01.06.16 |
Peter Thompson
BRD | Director/Board Member | 64 | 01.06.16 |
Natasha Hernday
BRD | Director/Board Member | 52 | 10.12.20 |
Director/Board Member | 45 | 24.04.18 | |
Xiang Ming Cui
BRD | Director/Board Member | 55 | 18.01.19 |
Jörn Drappa
BRD | Director/Board Member | 60 | 18.07.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 68 597 527 | 65 407 700 ( 95,35 %) | 0 | 95,35 % |
Unternehmenskontakt
Alpine Immune Sciences, Inc.
188 East Blaine Street Suite 200
98102, Seattle
+
http://www.alpineimmunesciences.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+9,42 % | 114 Mrd. | |
+11,84 % | 104 Mrd. | |
-14,15 % | 22,41 Mrd. | |
-1,05 % | 22,28 Mrd. | |
-5,29 % | 19,07 Mrd. | |
-38,29 % | 18 Mrd. | |
-4,16 % | 17,89 Mrd. | |
+7,99 % | 14,28 Mrd. | |
+36,24 % | 12,55 Mrd. |